ReviewClinical medicine insights. Circulatory, respiratory and pulmonary medicine2015
Management of Pneumocystis jirovecii Pneumonia in Kidney Transplantation to Prevent Further Outbreak.
Review in Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Risk Factors for Pneumocystis Jirovecii Pneumonia Among Kidney Transplant Recipients in Southeast France: A 10 Years Case-Control Study.Clinical transplantation · 2026Article
- A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.BMC infectious diseases · 2024Article
- Risk factors for Pneumocystis pneumonia with acute respiratory failure among kidney transplant recipients.BMC nephrology · 2023Article
- Article
- Efficacy of Low-Dose Trimethoprim/Sulfamethoxazole for the Treatment ofInfection and drug resistance · 2021Article
- Outbreak-Causing Fungi: Pneumocystis jirovecii.Mycopathologia · 2020Review
- Fungal Pathogens in CF Airways: Leave or Treat?Mycopathologia · 2018Review
- Hypercalcaemia preceding diagnosis ofClinical kidney journal · 2017Article
- Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak ofTransplantation direct · 2017Article
- Severe Cytomegalovirus Reactivation in Patient with Low-Grade Non-Hodgkin's Lymphoma after Standard Chemotherapy.Case reports in hematology · 2017Article
- Current Developments in Interstitial Lung Disease.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2015Article
- A Case ofCase reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of Pneumocystis jirovecii pneumonia (PJP) among kidney transplant recipients is emerging worldwide. It is important to control nosocomial PJP infection. A delay in diagnosis and treatment increases the number of reservoir patients and the number of cases of respiratory failure and death. Owing to the large number of kidney transplant recipients compared to other types of organ transplantation, there are greater opportunities for them to share the same time and space. Although the use of trimethoprim-sulfamethoxazole (TMP-SMX) as first choice in PJP prophylaxis is valuable for PJP that develops from infections by trophic forms, it cannot prevent or clear colonization, in which cysts are dominant. Colonization of P. jirovecii is cleared by macrophages. While recent immunosuppressive therapies have decreased the rate of rejection, over-suppressed macrophages caused by the higher levels of immunosuppression may decrease the eradication rate of colonization. Once a PJP cluster enters these populations, which are gathered in one place and uniformly undergoing immunosuppressive therapy for kidney transplantation, an outbreak can occur easily. Quick actions for PJP patients, other recipients, and medical staff of transplant centers are required. In future, lifelong prophylaxis may be required even in kidney transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.